Personalizing Breast Cancer Care: Pharmacist Strategies for Optimizing Oral Therapy Outcomes

This activity was originally presented live at Asembia's AXS26 Summit in Las Vegas, Nevada

Program Description

The treatment paradigm for breast cancer is shifting rapidly toward a personalized, oral-first approach. This shift is driven by two major factors: precision and autonomy. The integration of genomic testing has allowed oncology treatment regimens to move past traditional chemotherapies and instead use highly specific oral targeted therapies dictated by the tumor's molecular signature. However, shifting the site of care introduces unique challenges in clinical stewardship. Unlike treatment administered in clinic, where adherence is supervised, real-world data show that adherence to oral targeted agents can drop to 40% due to adverse effects and financial toxicity. This session will provide a clear, evidence-based framework for the clinical implications of key predictive biomarkers for oral targeted therapy alignment in both the adjuvant and metastatic breast cancer settings. Beyond drug selection, this activity addresses the practical complexities of long-term breast cancer management. Attendees will gain actionable insights into class-specific adverse effect mitigation strategies, ranging from managing hyperglycemia associated with PI3K inhibitors to the hematologic profiles of CDK4/6 inhibitors. Faculty presenters will also outline the logistical hurdles of oral therapies for breast cancer, such as navigating prior authorizations, specialty pharmacy coordination, and financial toxicity, ensuring accessible care for patients. The program features expert-led patient case discussions to support oncology pharmacists in translating high-level clinical trial data into actionable interventions for patients with breast cancer receiving oral therapies.

Target audience: Specialty pharmacists
Type of Activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply knowledge of key biomarkers and genomic alterations across breast cancer subtypes to support personalized therapy selection and sequencing of oral targeted treatments.
• Integrate emerging clinical data on oral targeted therapies across HR+, HER2+, and BRCA-mutated breast cancers to support evidence-based treatment decisions.
• Identify common adverse events and adherence barriers associated with oral targeted therapies in breast cancer to support pharmacist-led strategies for monitoring, prevention, and management.
• Explore pharmacist-driven strategies to improve access, affordability, and care coordination for patients receiving oral targeted breast cancer therapies through specialty pharmacy services.